AAM
LYEL icon

Advisors Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Advisors Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4K Hold
567
– – ﹤0.01% 1384
2025
Q4 		$17.5K Hold
567
– – ﹤0.01% 1360
2025
Q3 		$9.21K Sell
567
-8
-1% -$91 ﹤0.01% 1382
2025
Q2 		$5.08K Sell
575
-6
-1% -$55 ﹤0.01% 1403
2025
Q1 		$6.25K Buy
+581
New +$7.12K ﹤0.01% 1426

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Advisors Asset Management's LYEL Position: Q1 2026 in Review

Advisors Asset Management held its Lyell Immunopharma (LYEL) position steady in Q1 2026 at 567 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1384.

Advisors Asset Management first reported a position in LYEL in Q1 2025 and has held it in 5 quarters since. The position peaked at $17.5K in Q4 2025. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Advisors Asset Management held 567 shares of Lyell Immunopharma worth $11.4K as of Q1 2026.
  • Advisors Asset Management left its Lyell Immunopharma share count unchanged in Q1 2026.
  • Lyell Immunopharma made up ﹤0.01% of Advisors Asset Management's portfolio in Q1 2026, its #1384 holding.
  • Advisors Asset Management first reported a position in Lyell Immunopharma in Q1 2025 and has held it in 5 quarters since.
  • Advisors Asset Management's Lyell Immunopharma position peaked at $17.5K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Advisors Asset Management's 13F filing for Q1 2026, filed 15 May 2026.